The cancer diagnostics company BiBBInstruments AB announced on Tuesday the successful use of EndoDrill GI during a live broadcasted biopsy procedure at Hospital Pedro Hispano in Porto, Portugal.
The procedure, which involved sampling a pancreatic tumour, was conducted by Dr Francisco Baldaque Silva and broadcast during the Portuguese Society of Gastrointestinal Endoscopy's annual event, Live Sped 2025.
EndoDrill GI, the world's first CE-marked electric-driven biopsy instrument for endoscopy, was tested in real-time, demonstrating its capabilities. The procedure received positive feedback from both the team and the audience, with praise for the high-quality core biopsies.
Dr Baldaque Silva suggested the live biopsy after using EndoDrill GI at both Karolinska University Hospital and Hospital Pedro Hispano. EndoDrill GI is used for EUS-guided tissue sampling across various gastrointestinal indications, including the pancreas, stomach and liver. The successful demonstration marks a significant milestone for BiBBInstruments AB's product.
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Photocure study supports cost-effectiveness of blue light cystoscopy
Apotex receives Health Canada approval for a generic Ozempic equivalent
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review